Our evaluation of a racially/ethnically diverse cohort of women with unilateral breast cancer with pathogenic variants in BRCA1/2 showed no racial/ethnic difference in CPM use, but there was a higher post-CPM hazard of death among non-Whites than among Whites. This evidence concerns the gene BRCA1 and breast carcinoma.